<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0204245145
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1994
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIPRAM 20MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        111.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="H. LUNDBECK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            H. LUNDBECK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            H. LUNDBECK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How does Cipram work</strong></p><p>Cipram belongs to a group of antidepressants called Selective Serotonin Reuptake Inhibitors (SSRIs). These medicines act on the serotonin-system in the brain by increasing the serotonin level. Disturbances in the serotonin-system are considered an important factor in the development of depression and related diseases.</p><p><strong>What is Cipram used for</strong></p><p>Cipram contains citalopram and is used to treat depression and when you feel better, to help prevent these symptoms recurring.</p><p>Further, Cipram is used for long-term treatment to prevent the occurrence of new depressive episodes in patients who have recurrent depressions.</p><p>Cipram is also beneficial in relieving symptoms in patients prone to panic attacks</p><p>Your doctor, however, may prescribe Cipram for another purpose. Ask your doctor if you have any questions about why Cipram has been prescribed for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Cipram</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to citalopram or any of the other ingredients of Cipram (listed in section 6 )</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take other medicines which belongs to a group called monoamine oxidase inhibitors (MAOIs). MAOIs include medicines such as phenelzine, iproniazid, isocarboxazid, nialamide, tranylcypromine, selegiline (used in the treatment of Parkinson&acute;s disease), moclobemide (used in the treatment of depression) and linezolid (an antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at the same time as taking pimozide</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are born with or have had an episode of abnormal heart rhythm (seen at ECG; an examination to evaluate how the heart is functioning)</p><p>Even if you have finished taking MAOIs you will need to wait 2 weeks before you start getting your Cipram treatment.</p><p>One day must elapse after you have finished taking moclobemide.</p><p>After stopping Cipram you must allow 1 week before taking any MAOI.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Warnings and precautions<br />Please tell your doctor if you have any other condition or illness, as your doctor may need to take this into consideration. In particular, tell your doctor:<br />&bull;&nbsp;&nbsp; &nbsp;if you have episodes of mania or panic disorder<br />&bull;&nbsp;&nbsp; &nbsp;if you suffer from impaired liver or kidney function. Your doctor may need to adjust your dosage<br />&bull;&nbsp;&nbsp; &nbsp;if you have diabetes. Treatment with Cipram may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.<br />&bull;&nbsp;&nbsp; &nbsp;if you have epilepsy. Treatment with Cipram should be stopped if seizures occur or if there is an increase in the seizure frequency (see also section 4 &ldquo;Possible side effects&quot;)<br />&bull;&nbsp;&nbsp; &nbsp;if you have some kind of bleeding disorders, or if you are pregnant (see &lsquo;Pregnancy, breast-feeding and fertility&rsquo;)<br />&bull;&nbsp;&nbsp; &nbsp;if you have a decreased level of sodium in the blood<br />&bull;&nbsp;&nbsp; &nbsp;if you are receiving electroconvulsive treatment<br />&bull;&nbsp;&nbsp; &nbsp;if you suffer or have suffered from heart problems or have recently had a heart attack<br />&bull;&nbsp;&nbsp; &nbsp;if you have a low resting heart-rate and/or you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets)<br />&bull;&nbsp;&nbsp; &nbsp;if you experience a fast or irregular heartbeat, fainting, collapse or dizziness on standing up which may indicate abnormal functioning of the heart rate<br />&bull;&nbsp;&nbsp; &nbsp;if you have or have previously had eye problems, such as certain kinds of glaucoma (increased pressure in the eye).</p><p><br />Please consult your doctor, even if these statements were applicable to you at any time in the past.</p><p>Please note<br />Some patients with manic-depressive illness may enter into a manic phase. This is characterized by unusual and rapidly changing ideas, inappropriate happiness and<br />excessive physical activity. If you experience this, contact your doctor.</p><p>Symptoms such as restlessness or difficulty to sit or stand still (akathisia) can also occur during the first weeks of the treatment. Tell your doctor immediately if you experience these symptoms.</p><p>Thoughts of suicide and worsening of your depression or anxiety disorder<br />If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:<br />&bull;&nbsp;&nbsp; &nbsp;If you have previously had thoughts about killing or harming yourself<br />&bull;&nbsp;&nbsp; &nbsp;If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in young adults (less than 25 years old) with psychiatric conditions who were treated with an antidepressant.</p><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.</p><p>You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p>Children and adolescents under 18 years of age<br />Cipram should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempts, suicidal thoughts and hostility (predominately aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Cipram for patients under 18 because he/she decides that this is in their best interest. If your doctor has prescribed Cipram for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any symptoms listed above develop or worsen when patients under 18 are taking Cipram.</p><p>Special information relating to your disease<br />As with other medicines used to treat depression or related diseases, the improvement is not achieved immediately. After the start of Cipram treatment it may take several weeks before you experience any improvement.</p><p>In the treatment of panic disorder it usually takes 2-4 weeks before any improvement is seen.</p><p>In the beginning of the treatment certain patients may experience increased anxiety, which will disappear during the continued treatment. Therefore, it is very important that you follow exactly your doctor&rsquo;s orders and do not stop the treatment or change the dose without consulting your doctor.</p><p>Occasionally, the symptoms of depression or panic disorder may include thoughts of suicide or self-harm. It is possible that these symptoms continue or get worse until the full antidepressant effect of the medicine becomes apparent. This is more likely to occur if you are a young adult, i.e. under 25 years of age and you have not used antidepressive medicines before.</p><p>Some patients with manic-depressive illness may enter into a manic phase. This is characterized by unusual and rapidly changing ideas, inappropriate happiness and excessive physical activity. If you experience this, contact your doctor.</p><p>Symptoms such as restlessness or difficulty to sit or stand still can also occur during the first weeks of the treatment. Tell your doctor immediately if you experience these symptoms.</p><p>Sometimes you may be unaware of the above-mentioned symptoms and therefore you may find it helpful to ask a friend of relative to help you to observe the possible signs of change in your behavior.</p><p>Tell your doctor immediately or contact the nearest hospital if you have distressing thoughts or experiences or if any of the above-mentioned symptoms occurs during the treatment.<br />Other medicines and Cipram<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription.</p><p>Some medicinal products may affect the action of another and this can sometimes cause serious adverse reactions.</p><p>Tell your doctor if you are taking any of the following medicines:<br />&bull;&nbsp;&nbsp; &nbsp;&rdquo;Non-selective monoamine oxidase inhibitors (MAOIs)&rdquo;, containing phenelzine, iproniazid, isocarboxazid, nialamide, and tranylcypromine as active substance. If you have taken any of these medicines you will need to wait 14 days before you start taking Cipram. After stopping Cipram you must allow 7 days before taking any of these medicines<br />&bull;&nbsp;&nbsp; &nbsp;&ldquo;Reversible, selective MAO-A inhibitors&rdquo;, containing moclobemide (used to treat depression)<br />&bull;&nbsp;&nbsp; &nbsp;the antibiotic linezolid<br />&bull;&nbsp;&nbsp; &nbsp;lithium (used in the prophylaxis and treatment of manic-depressive disorder) and tryptophan<br />&bull;&nbsp;&nbsp; &nbsp;imipramine and desipramine (both used to treat depression)<br />&bull;&nbsp;&nbsp; &nbsp;&ldquo;Irreversible MAO-B inhibitors&rdquo;, containing selegiline (used to treat Parkinson&#39;s disease); these increase the risk of side effects. The dose of selegiline must not exceed 10 mg per day<br />&bull;&nbsp;&nbsp; &nbsp;metoprolol (used for high blood pressure and/or heart disease); the blood levels of metoprolol are increased, but signs of increased effect or side effects of metoprolol have not been recorded<br />&bull;&nbsp;&nbsp; &nbsp;sumatriptan and similar medicines (used to treat migraine) and tramadol and similar medicines (used against severe pain) these increase the risk of side effects; if you get any unusual symptoms when using this combination you&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; should see your doctor<br />&bull;&nbsp;&nbsp; &nbsp;cimetidine, when used in high doses, lansoprazole and omeprazole &nbsp;(used to treat stomach ulcers); fluconazole (used to treat fungal infections), fluvoxamine (antidepressant) and ticlopidine (used to reduce the risk of stroke) may cause increased blood levels of citalopram &nbsp;but increased side effects of Cipram have not been recorded<br />&bull;&nbsp;&nbsp; &nbsp;drugs known to affect the platelet function (e.g. some antipsychotic drugs, tricyclic antidepressants, acetylsalicylic acid (used as pain killers), non-steroidal anti-inflammatory drugs (used for arthritis)); slightly increased risk of bleeding abnormalities<br />&bull;&nbsp;&nbsp; &nbsp;oral anticoagulants (drugs which work by preventing clotting of the blood); as it may increase the risk of bleeding abnormalities&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;St John&#39;s wort (hypericum perforatum) (a herbal remedy used for depression) - concomitant intake with Cipram may increase the risk of side effects<br />&bull;&nbsp;&nbsp; &nbsp;Medicines that induce low levels of potassium and/or magnesium&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;mefloquin (used to treat Malaria), bupropion (used to treat depression) and tramadol (used to treat severe pain) due to a possible risk of a lowered threshold for seizures<br />&bull;&nbsp;&nbsp; &nbsp;neuroleptics (medicines to treat schizophrenia, psychosis) due to a possible risk of a lowered threshold for seizures, and antidepressants<br />&bull;&nbsp;&nbsp; &nbsp;Class IA and III antiarrhytmics, antipsychotics (e.g. fentiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimi-crobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarian treatment particularly holofantrine), certain anti-histamines (astemizole, mizolastine)</p><p>Taking Cipram with food, drink and alcohol<br />Cipram can be taken with or without food (see section 3 &ldquo;How to take Cipram&rdquo;).</p><p>Cipram has been shown not to increase the effects of alcohol. Nevertheless, it is recommended not to drink alcohol during treatment with Cipram.</p><p><br />Pregnancy, breast-feeding and fertility<br />Inform your doctor if you are pregnant or planning to become pregnant. Pregnant women should not usually take Cipram or should mothers breast-feed their babies while taking this medicine, unless you and your doctor have discussed the risks and benefits involved.</p><p>If you take Cipram during the last 3 months of your pregnancy and until the date of birth you should be aware that the following effects may be seen in your newborn: trouble with breathing, bluish skin, fits, body temperature changes, feeding difficulties, vomiting, low blood sugar, stiff or floppy muscles, vivid reflexes, tremor, jitteriness, irritability, lethargy, constant crying, sleepiness and sleeping difficulties. If your newborn baby has any of these symptoms, please contact your doctor immediately.</p><p>Make sure your midwife and/or doctor know you are on Cipram. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like Cipram may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.</p><p>If you take Cipram near the end of your pregnancy there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking Cipram so they can advise you.</p><p>Citalopram has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet.</p><p>&nbsp;</p><p>Driving and using machines<br />Cipram generally does not cause drowsiness; however, if you feel dizzy or sleepy when you start to take this medicine, do not drive or work any tools or machinery until these effects wear off.</p><p><br />Important information about some of the ingredients of Cipram<br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take</strong></p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><u>Adults</u></p><p><em>Depression</em></p><p>The usual dose is 20 mg per day. The dose may be increased by your doctor to a maximum of 40 mg per day.</p><p><em>Panic disorder</em></p><p>The starting dose is 10&nbsp;mg per day for the first week before increasing the dose to 20-30&nbsp;mg per day. The dose may be increased by your doctor to a maximum of 40&nbsp;mg per day.</p><p>&nbsp;</p><p><u>Elderly patients (above 65 years of age)</u></p><p>The starting dose should be decreased to half of the recommended dose, e.g. 10-20 mg per day. Elderly patients should not usually receive more than 20 mg per day.</p><p>&nbsp;</p><p><u>Patients with special risks</u></p><p>Patients with liver complaints should not receive more than 20 mg per day.</p><p>&nbsp;</p><p><u>Children and adolescents (&lt; 18 years)</u></p><p>Cipram should not be given to children or adolescents. For further information please see section 2 &ldquo;What you need to know before you take Cipram&rdquo;.</p><p><strong>How and when to take Cipram</strong></p><p>Cipram is taken every day as a single daily dose.</p><p>Cipram can be taken any time of the day with or without food.</p><p>Swallow the tablets with a drink of water. Do not chew them (they have a bitter taste).</p><p><strong>Duration of treatment</strong></p><p>Like other medicines for depression, these may take a few weeks before you feel any improvement. Continue to take Cipram even if it takes some time before you feel any improvement in your condition.</p><p>&nbsp;</p><p>Never change the dose of the medicine without talking to your doctor first.</p><p>&nbsp;</p><p>The duration of treatment is individual, usually at least 6 months. Continue to take the tablets for as long as your doctor recommends. Do not stop taking them even if you begin to feel better, unless you are told to do so by your doctor. The underlying illness may persist for a long time and if you stop your treatment too soon your symptoms may return.</p><p>&nbsp;</p><p>Patients who have recurrent depressions benefit from continued treatment, sometimes for several years, to prevent the occurrence of new depressive episodes.</p><p><strong>If you take more Cipram than you should</strong></p><p>If you think that you or anyone else may have taken too much Cipram contact your doctor or nearest hospital emergency department immediately. Do</p><p>this&nbsp;even if there are no signs of discomfort or poisoning. Take the Cipram box/container with you if you go to a doctor or hospital.</p><p>Some of the signs of an overdose could be life-threatening irregular heart beat, convulsion, change in heart rhythm, drowsiness, coma, vomiting, tremor, decreased blood pressure, increased blood pressure, nausea (feeling sick), Serotonin syndrome (see section 4), agitation, dizziness, dilated pupils of the eye, sweating, bluish skin, hyperventilation.</p><p><strong>If you forget to take Cipram</strong></p><p>Do not take a double dose to make up for forgotten doses.</p><p>If you forget to take a dose, and you remember before you go to bed, take it straight away. Carry on as usual the next day. If you only remember during the night, or the next day, leave out the missed dose and carry on as usual.</p><p><strong>If you stop taking Cipram</strong></p><p>Do not stop taking Cipram until your doctor tells you to do so. When you have completed your course of treatment, it is generally advised that the dose of Cipram is gradually reduced over a number of weeks.</p><p>Abrupt cessation of the medication may cause mild and transient discontinuation symptoms such as dizziness, feelings like pins and needles, sleep disturbances (vivid dreams, nightmares, inability to sleep), feeling anxious, headaches, feeling sick (nausea), vomiting, sweating, feeling restless or agitated, tremor, feeling confused or disorientated, feeling emotional or irritable, diarrhoea (loose stools), visual disturbances, fluttering or pounding heartbeat (palpitations).</p><p>When you have completed your course of treatment it is therefore advised that the dose of Cipram is gradually reduced over a couple of weeks rather than stopped abruptly.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Cipram can cause side effects, although not everybody gets them.</p><p>The side effects usually disappear after a few weeks of treatment. Please be aware that many of the effects may also be symptoms of your illness and therefore will improve when you start to get better.</p><p>Some patients have reported the following serious side effects.</p><p>If you get any of the following symptoms you should stop taking Cipram and see your doctor immediately:<br />&bull;&nbsp;&nbsp; &nbsp;High fever, agitation, confusion, trembling and abrupt contractions of muscles; this may be signs of a rare condition called serotonin syndrome which has been reported with the combined use of antidepressants.<br />&bull;&nbsp;&nbsp; &nbsp;If you experience swelling of skin, tongue, lips, or face, or have difficulties breathing or swallowing (allergic reaction).<br />&bull;&nbsp;&nbsp; &nbsp;Unusual bleeds, including gastrointestinal bleeds</p><p>Rare but serious side effects ( may affect up to 1 in &nbsp;1,000 patients)<br />If you get any of the following symptoms you should stop taking Cipram and see your doctor immediately:<br />&bull;&nbsp;&nbsp; &nbsp;Hyponatraemia: low bloodlevels of sodium which can cause tiredness, confusion, and muscle twitching.</p><p>The following side effects are often mild and usually disappear after a few days&rsquo; treatment. Be aware that several of the below mentioned effects also can be symptoms of your illness and therefore wanes when you start to get better.</p><p>If side effects are troublesome or last for more than a few days tell your doctor.</p><p>Dry mouth increases the risk of caries. Therefore you should brush your teeth more often than usual.</p><p>Very common (may affect more than 1 in 10 people):<br />&bull;&nbsp;&nbsp; &nbsp;Sleepiness<br />&bull;&nbsp;&nbsp; &nbsp;Difficulty in sleeping<br />&bull;&nbsp;&nbsp; &nbsp;Increased sweating<br />&bull;&nbsp;&nbsp; &nbsp;Dry mouth<br />&bull;&nbsp;&nbsp; &nbsp;Nausea (feeling sick)</p><p>Common (may affect up to 1 in 10 people):<br />&bull;&nbsp;&nbsp; &nbsp;Decreased appetite<br />&bull;&nbsp;&nbsp; &nbsp;Agitation<br />&bull;&nbsp;&nbsp; &nbsp;Decreased sexual drive<br />&bull;&nbsp;&nbsp; &nbsp;Anxiety<br />&bull;&nbsp;&nbsp; &nbsp;Nervousness<br />&bull;&nbsp;&nbsp; &nbsp;Confusional state<br />&bull;&nbsp;&nbsp; &nbsp;Abnormal dreams<br />&bull;&nbsp;&nbsp; &nbsp;Tremor<br />&bull;&nbsp;&nbsp; &nbsp;Tingling or numbness in the hands or feet<br />&bull;&nbsp;&nbsp; &nbsp;Dizziness<br />&bull;&nbsp;&nbsp; &nbsp;Disturbance in attention<br />&bull;&nbsp;&nbsp; &nbsp;Ringing in the ears (tinnitus)<br />&bull;&nbsp;&nbsp; &nbsp;Yawning<br />&bull;&nbsp;&nbsp; &nbsp;Diarrhoea<br />&bull;&nbsp;&nbsp; &nbsp;Vomiting<br />&bull;&nbsp;&nbsp; &nbsp;Constipation<br />&bull;&nbsp;&nbsp; &nbsp;Itching<br />&bull;&nbsp;&nbsp; &nbsp;Pain in muscle and joints<br />&bull;&nbsp;&nbsp; &nbsp;Men may experience problems with ejaculation and erection<br />&bull;&nbsp;&nbsp; &nbsp;Women may experience, failure to achieve an orgasm<br />&bull;&nbsp;&nbsp; &nbsp;Fatigue<br />&bull;&nbsp;&nbsp; &nbsp;Fever<br />&bull;&nbsp;&nbsp; &nbsp;Prickling of the skin<br />&bull;&nbsp;&nbsp; &nbsp;Decreased weight</p><p>Uncommon (may affect up to 1 in 100 people):<br />&bull;&nbsp;&nbsp; &nbsp;Cutaneous bleeding disorder (easily bruising)<br />&bull;&nbsp;&nbsp; &nbsp;Increased appetite<br />&bull;&nbsp;&nbsp; &nbsp;Aggression<br />&bull;&nbsp;&nbsp; &nbsp;Depersonalization<br />&bull;&nbsp;&nbsp; &nbsp;Hallucination<br />&bull;&nbsp;&nbsp; &nbsp;Mania<br />&bull;&nbsp;&nbsp; &nbsp;Fainting<br />&bull;&nbsp;&nbsp; &nbsp;Enlarged pupils<br />&bull;&nbsp;&nbsp; &nbsp;Fast heart beat<br />&bull;&nbsp;&nbsp; &nbsp;Slow heart beat<br />&bull;&nbsp;&nbsp; &nbsp;Nettle rash<br />&bull;&nbsp;&nbsp; &nbsp;Loss of hair<br />&bull;&nbsp;&nbsp; &nbsp;Rash<br />&bull;&nbsp;&nbsp; &nbsp;Light sensitiveness<br />&bull;&nbsp;&nbsp; &nbsp;Difficulties urinating<br />&bull;&nbsp;&nbsp; &nbsp;Excessive menstrual bleeding<br />&bull;&nbsp;&nbsp; &nbsp;Swelling of the arms or legs<br />&bull;&nbsp;&nbsp; &nbsp;Increased weight</p><p>Rare (may affect up to 1 in 1,000 people):<br />&bull;&nbsp;&nbsp; &nbsp;Convulsions<br />&bull;&nbsp;&nbsp; &nbsp;Involuntary movements<br />&bull;&nbsp;&nbsp; &nbsp;Taste disturbance<br />&bull;&nbsp;&nbsp; &nbsp;Bleeding<br />&bull;&nbsp;&nbsp; &nbsp;Hepatitis</p><p>Not known (frequency cannot be estimated from the available data):<br />&bull;&nbsp;&nbsp; &nbsp;Thoughts of harming yourself or thoughts of killing yourself, see also section &ldquo;Warning and precautions&rdquo;<br />&bull;&nbsp;&nbsp; &nbsp;Reduction in blood platelets, which increases risk of bleeding or bruising<br />&bull;&nbsp;&nbsp; &nbsp;Hypersensitivity (rash)<br />&bull;&nbsp;&nbsp; &nbsp;Serious allergic reaction which causes difficulty in breathing or dizziness<br />&bull;&nbsp;&nbsp; &nbsp;Increase in the amount of urine excreted<br />&bull;&nbsp;&nbsp; &nbsp;Hypokalaemia: low blood levels of potassium which can cause muscle weakness,<br />&bull;&nbsp;&nbsp; &nbsp;twitching or abnormal heart rhythm<br />&bull;&nbsp;&nbsp; &nbsp;Panic attack<br />&bull;&nbsp;&nbsp; &nbsp;Grinding one&rsquo;s teeth<br />&bull;&nbsp;&nbsp; &nbsp;Restlessness<br />&bull;&nbsp;&nbsp; &nbsp;Unusual muscle movements or stiffness<br />&bull;&nbsp;&nbsp; &nbsp;Akathisia (involuntary movements of the muscles)<br />&bull;&nbsp;&nbsp; &nbsp;Visual disturbance<br />&bull;&nbsp;&nbsp; &nbsp;Low blood pressure<br />&bull;&nbsp;&nbsp; &nbsp;Nosebleed<br />&bull;&nbsp;&nbsp; &nbsp;Bleeding disorders including skin and mucous bleeding (ecchymosis)<br />&bull;&nbsp;&nbsp; &nbsp;Heavy vaginal bleeding shortly after birth (postpartum haemorrhage), see &lsquo;Pregnancy, breast-feeding and fertility&rsquo; in section 2 for more information.<br />&bull;&nbsp;&nbsp; &nbsp;Sudden swelling of skin or mucosa<br />&bull;&nbsp;&nbsp; &nbsp;Painful erections<br />&bull;&nbsp;&nbsp; &nbsp;Flow of milk in men and women that are not nursing<br />Irregular menstrual period<br />&bull;&nbsp;&nbsp; &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;Abnormal liver function test<br />&bull;&nbsp;&nbsp; &nbsp;An increased risk of bone fractures has been observed in patients taking this type of medicines<br />&bull;&nbsp;&nbsp; &nbsp;Abnormal heart rhythm</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p>&nbsp;</p><p>Please report adverse drug events to:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa&nbsp;</p><p>Other GCC States:<br />- Please contact the relevant competent authority.<br />&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30 &deg;C.</p><p>Do not use this medicine after the expiry date, which is stated on the label or carton.</p><p>The expiry date refers to the last day of the month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away &nbsp;medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Cipram contains</strong></p><p>The active substance is citalopram (as hydrobromide).</p><p>Cipram film-coated tablets contain 20 mg citalopram (as citalopram hydrobromide).</p><p>The other ingredients are maize starch, lactose monohydrate, microcrystalline cellulose, copovidone, glycerol 85%, croscarmellose sodium, magnesium stearate.</p><p>Coating: Hypromellose 5, macrogol 400.</p><p>Colour: Titanium dioxide (E 171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Cipram looks like and contents of the pack

Cipram is presented as 20 mg film-coated tablets and are available in blister packs.

Description of Cipram tablets 
The 20 mg tablets are oval, white, scored, film-coated, marked with “C” and “N”.

Cipram is available in the following packs: 
28 in blister packs.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>H. Lundbeck A/S</p><p>Ottiliavej 9</p><p>2500 Valby</p><p>Denmark.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 September 2022


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم يُستخدم عقار سيبرام؟</strong></p><p dir="RTL">يحتوي عقار سيبرام على سيتالوبرام، ويُستخدم لعلاج الاكتئاب، وعند الشعور بتحسُّن، يُساعد على منع هذه الأعراض من التكرار.</p><p>&nbsp;</p><p dir="RTL">بالإضافية إلى أن العلاج طويل الأمد يمنع حدوث نوبات جديدة من الاكتئاب لدى المرضى ممن يعانون من حالات الاكتئاب المُتكررة.</p><p>&nbsp;</p><p dir="RTL">سيبرام هو أيضا مفيد في تخفيف الأعراض في المرضى عرضة لنوبات الذعر</p><p dir="RTL">&nbsp;</p><p dir="RTL">مع ذلك، فقد يصف لك طبيبك عقار سيبرام لغرض آخر. اسأل طبيبك إن كانت لديك أي أسئلة تتعلق بعقار سيبرام الموصوف لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تتناول عقار سيبرام في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كانت لديك حساسية (فرط حساسية) تجاه سيتالوبرام أو أي مكونات أخرى في عقار سيبرام (المدرجة في قسم: 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى تنتمي إلى مجموعة تُسمى مثبطات الأوكسيديز أحادي الأمين. تشمل مثبطات الأوكسيديز أحادي الأمين أدوية مثل: فينلزين وإبرونيازيد وأيزوكربوكسازيد ونيالمايد وترانيلسيبرومين وسيليجيلين (يُستَخدَم في علاج مرض الشلل الرعَّاش [مرض باركنسون]) وموكلوبيميد (يُستَخدَم في علاج الاكتئاب) ولينزوليد (مضاد حيوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناوُل بيموزيد بالتزامن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أصبت من قبل بنوبة من اضطراب النَّظم القلبي غير الطبيعي (يمكن التَّعرف عليها في &nbsp;تخطيط القلب؛ وهو فحص لتقييم أداء القلب) أو ولدت تعاني من ذلك.</p><p>&nbsp;</p><p dir="RTL">حتى إذا أوقفت تناوُل مثبطات أوكسيديز أحادي الأمين، فستحتاج للانتظار أسبوعين قبل بدء العلاج بعقار سيبرام.</p><p>&nbsp;</p><p dir="RTL">يجب أن يكون قد مر يوم على انتهائك من تناوُل موكلوبوميد.</p><p>&nbsp;</p><p dir="RTL">يجب أن يمر أسبوع واحد بعد التوقُّف عن تناوُل عقار سيبرام قبل تناوُل أيّ مثبط أوكسيديز أحادي الأمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p>من فضلك أخبر طبيبك إذا كان لديك أي حالة أو مرض آخر؛ حيث سيحتاج طبيبك إلى أخذ ذلك بعين الاعتبار. &nbsp;أخبر طبيبك لا سيما في الحالات التَّالية:<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تُعاني من نوبات من الهوس أو اضطراب الهلع.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تُعاني من قصور وظائف الكبد أو الكُلى. قد يحتاج طبيبك إلى تعديل جرعتك.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت مصابًا بمرض السُّكَّرِي. قد يُغيِّر العلاج بعقار سيبرام من التحكُّم في مستوى السكر بالدَّم. قد يستلزم الأمر تعديل جرعة الأنسولين و/أو الدَّواء الفموي الخافض لسكر الدَّم.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تُعاني من الصَّرع. يجب إيقاف العلاج بعقار سيبرام إذا حدثت نوبات تشنجية، أو إذا كان هناك زيادة في معدَّل تكرار النوبات التشنجية (انظر أيضًا قسم: 4 &quot;الآثار الجانبية المُحتمَلة&quot;).<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من أحد اضطرابات النزيف أو إذا كنت حاملاً (انظر &quot;الحمل والرضاعة والخصوبة&quot;).<br />&bull;&nbsp;&nbsp; &nbsp;إذا كان لديك انخفاض في مستوى الصوديوم بالدَّم.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تتلقى علاجًا بالتَّخليج الكهربائي.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تُعاني أو قد عانيت من مشاكل بالقلب أو تعرَّضت مؤخرًا لنوبة قلبية.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كان لديك انخفاض في معدَّل ضربات القلب أثناء الراحة و/أو كنت تعلم أن لديك حالة من &nbsp;استنزاف المِلْح نتيجة الإصابة بإسهال وقيء (إعياء) أو كنت تستخدم مُدِرات البول (أقراص الماء).<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تُعاني من سرعة أو عدم انتظام ضربات القلب، إغماء، هبوط الدَّورة الدَّموية أو الدوخة عند الوقوف مما يُشير إلى اضطراب مُعدَّل ضربات القلب.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تعاني أو عانيت من قبل من مشاكل في العين ، مثل أنواع معينة من الجلوكوما (زيادة الضغط في العين).</p><p>يُرجى استشارة الطبيب حتى وإن انطبق عليك ذلك في أيّ وقت في الماضي.</p><p>يُرجى ملاحظة ما يلي:<br />قد يُصاب بعض المرضى الذين يعانون &nbsp;من الهوس الإكتئابي بنوبات هوس. تتسم هذه الحالة بالأفكار غير المُعتادة وسريعة التغيُّر والسعادة بصورة غير ملائمة<br />النَّشاط البدني المفرط. إذا تعرَّضت لهذا، فاتصل بطبيبك.</p><p>لا تزال الأعراض مثل: التململ أو صعوبة الجلوس أو الثبات (تعذُّر الجلوس) أيضًا خلال الأسابيع الأولى من العلاج. أخبر طبيبك فورًا إذا تعرَّضت لهذه الأعراض.</p><p>اضطرابات الأفكار الانتحارية وتفاقم الاكتئاب لديك أو القلق<br />إذا كنت مكتئبًا و/أو إذا كنت تعاني اضطرابات القلق فيُمكِن في بعض الأحيان أن يكون لديك أفكار لإيذاء نفسك أو قتلها. قد تزداد هذه الأفكار عند بدء تناوُل مضادات الاكتئاب لأول مرة، نظرًا إلى أن جميع هذه الأدوية تستغرق وقتًا حتى تعمل، عادةً يستغرق الأمر أسبوعين تقريبًا ولكن في بعض الأحيان يستغرق فترة أطول.</p><p>قد تكون أكثر عُرضة للتفكير على هذا النحو:<br />&bull;&nbsp;&nbsp; &nbsp;إذا كان لديك سابقًا أفكارٌ بشأن قتل أو إيذاء نفسك.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت من الشباب البالغين. أظهرت المعلومات المستقاة من التجارب السريرية ارتفاع نسبة خطورة السلوك الانتحاري لدى البالغين الذين تقل أعمارهم عن 25 سنة ويُعانون من حالات نفسية ممن عُولجوا بأحد مضادات الاكتئاب.</p><p>إذا كان لديك أفكار حول إيذاء نفسك أو قتلها في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور.</p><p>قد تجد أنه من المفيد إخبار أحد الأقارب أو الأصدقاء المقربين أنك لديك اضطرابات تشمل الاكتئاب أو القلق، ومطالبتهم بقراءة هذه النَّشرة. قد تطلب منهم أن يخبروك بما إذا كانوا يعتقدون أن مرض الاكتئاب أو القلق يتفاقم لديك، أو ما إذا كانوا قلقين بشأن التغيرات الطارئة على سلوكك.</p><p>الأطفال والمراهقون أقل من 18 عامًا<br />عادةً، يجب ألا يتم استخدام عقار سيبرام في الأطفال والمراهقين أقل من 18 عامًا. يجب أيضًا أن تعرف أن المرضى الذين تقل أعمارهم عن 18 عامًا يكونون معرَّضين لزيادة مخاطر الإصابة بآثار جانبية مثل: محاولات الانتحار والأفكار الانتحارية والعداء (غالبًا عدوان وسلوك معارض وغضب) عندما يتناولون هذه الفئة من الأدوية. ورغم ذلك، &nbsp;مع ذلك فقد يصف الطبيب عقار سيبرام لمن هم أقل من 18 عامًا؛ لأنه ربما يرى أنه يصب في صالح المريض. إذا وصف طبيبك عقار سيبرام لمن هم أقل من 18 عامًا وترغب في مناقشة الأمر معه فيمكنك معاودة الاتصال به.&nbsp;<br />يجب أن تبلغ طبيبك في حالة ظهور أو تفاقم أيّ من الأعراض الواردة أعلاه إن كان المريض أقل من 18 عامًا ويتناول عقار سيبرام.</p><p>معلومات خاصَّة متعلقة بمرضك<br />كما هو الحال مع الأدوية الأخرى التي تُستَخدَم لعلاج الاكتئاب أو الأمراض ذات الصلة، لا يتحقق التحسُّن فورًا. بعد بدء العلاج بعقار سيبرام قد يستغرق الأمر عدة أسابيع قبل أن تلاحظ أيّ تحسُّن.</p><p>عادةً ما يستغرق الأمر في علاج اضطراب الهلع من أسبوعين إلى أربعة أسابيع قبل ملاحظة أيّ تحسُّن.</p><p>في بداية العلاج قد يتعرَّض بعض المرضى إلى قلق متزايد، والذي سيزول مع العلاج المستمر. لذا فمن المهم للغاية أن تتبع أوامر طبيبك بالضبط، وألا تتوقف عن تناوُل العلاج أو تغيِّر الجرعة دون استشارته.</p><p>أحيانًا، قد &nbsp;تشمل أعراض الاكتئاب أو اضطراب الهلع أفكارًا انتحارية أو إيذاء النفس. من المُمكن أن تستمر هذه الأعراض أو تتفاقم حتى يظهر تأثير الدَّواء المضاد للاكتئاب. يُعَد هذا أكثر عُرضة للحدوث إذا كنت من الشباب البالغين، أي يقل عُمرُك عن 25 عامًا ولم تستخدم أدوية مضادة للاكتئاب من قبل.</p><p>قد يُصاب بعض المرضى الذين يعانون هوسًا اكتئابيًّا بنوبات هوس. تتسم هذه الحالة بالأفكار غير المُعتادة وسريعة التغيُّر والسعادة بصورة غير ملائمة والنشاط البدني المفرط. إذا تعرَّضت لهذا، فاتصل بطبيبك.</p><p>لا تزال الأعراض مثل: التململ أو صعوبة الجلوس أو الوقوف قابلة للحدوث أيضًا خلال الأسابيع الأولى من العلاج. أخبر طبيبك فورًا إذا تعرَّضت لهذه الأعراض.</p><p>في بعض الأحيان قد لا تكون على دراية بالأعراض المذكورة أعلاه، وبالتَّالي قد تجد أنه من المفيد أن تطلب من صديق أو قريب مساعدتك في رصد العلامات المُحتَمَلة لحدوث تغيُّر في سلوكك.</p><p>أخبر طبيبك فورًا أو اتصل بأقرب مستشفى إذا كان لديك أفكار أو خبرات مزعجة أو إذا حدث أيّ من الأعراض المذكورة أعلاه أثناء العلاج.</p><p>تناوُل عقار سيبرام مع أدوية أخرى<br />يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أيّة أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.</p><p>قد تُؤثر بعض المنتجات الدَّوائية على تأثير أخرى، وقد يُؤدي ذلك إلى حدوث تفاعلات عكسية خطيرة.</p><p>أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية:<br />&bull;&nbsp;&nbsp; &nbsp;&quot;مثبطات أوكسيديز أحادي الأمين غير الانتقائية (MAOIs)&quot;، المحتوية على المواد الفعَّالة فينلزين، وإبرونيازيد، وأيزوكاربوكسازيد، ونيالاميد، وترانيلسيبرومين. إذا كنت قد تناولت أيًّا من هذه الأدوية فستحتاج إلى الانتظار لمدة 14 يومًا قبل البدء في تناوُل عقار سيبرام. بعد التوقُّف عن تناوُل عقار سيبرام يجب مراعاة مرور 7 أيام قبل تناوُل أيّ من هذه الأدوية<br />&bull;&nbsp;&nbsp; &nbsp;&quot;مثبطات أوكسيديز أحادي الأمين &quot;أ&quot; الانتقائية القابلة للارتداد&quot;، التي تحتوي على موكلوبيميد (يُستَخدَم لعلاج الاكتئاب).<br />&bull;&nbsp;&nbsp; &nbsp;المضاد الحيوي لينزوليد<br />&bull;&nbsp;&nbsp; &nbsp;الليثيوم (يُستخدم في العلاجات الوقائية وعلاج اضطرابات الهوس الاكتئابي) وتريبتوفان<br />&bull;&nbsp;&nbsp; &nbsp;إيميبرامين وديسيبرامين (كلاهما يُستَخدَم لعلاج الاكتئاب)<br />&bull;&nbsp;&nbsp; &nbsp;&quot;مثبطات أوكسيديز أحادي الأمين &quot;ب&quot; غير القابلة للارتداد&quot;، المحتوية على سيليجيلين (يُستَخدَم لعلاج مرض الشلل الرعَّاش [مرض باركنسون]): قد تزيد من خطورة حدوث آثار جانبية. يجب ألا تتجاوز جرعة سيليجيلين 10 مجم يوميًّا<br />&bull;&nbsp;&nbsp; &nbsp;ميتوبرولول (يُستخدم لعلاج ارتفاع ضغط الدَّم و/أو أمراض القلب)، ترتفع مستويات ميتوبرولول في الدّم، لكن لم يتم تسجيل زيادة التَّأثير أو الآثار الجانبية لميتوبرولول.<br />&bull;&nbsp;&nbsp; &nbsp;سوماتريبتان والأدوية المماثلة (التي تُستَخدَم لعلاج الصُّداع النصفي) وترامادول والأدوية المماثلة (يُستَخدَم كمسكن للألم الشديد) من خطر الآثار الجانبية، إذا أُصِبت بأيّ أعراض غير مُعتادة عند استخدام هذه التركيبة فعليك بالرجوع إلى طبيبك</p><p>عند استخدام جرعات مرتفعة من سیمیتیدین, لانسوبرازول وأومیبرازول (المستخدم لعلاج قرح المعدة)، فلوكونازول (لعلاج &middot;</p><p>الالتھابات الفطریة) ، فلوفوكسامین (مضاد للاكتئاب) وتیكلوبیدین (یستخدم لتقلیل مخاطر السكتة الدماغیة) ,ربما ترتفع</p><p>مستویات عقار سیبرام في الدمَّ لدیك، لكن لم یتم رصد زیادة في الآثار الجانبیة لعقار سیبرام .</p><p>الأدویة المعروفة بتأثیرھا على وظائف صفائح الدَّم (على سبیل المثال: بعض مضادات الذھان، مضادات الاكتئاب ثلاثیة &middot;</p><p>الحلقات، حمض أسیتیل السالیسیلیك (الذي یُستخدم كمسكن ألم)، الأدویة المضادة للالتھابات غیر الستیرویدیة (التي تُستخ دم</p><p>لعلاج التھاب المفاصل)، زیادة طفیفة في خطر الإصابة باضطرابات النزیف</p><p>مضادات التخثر الفمویة (الأدویة التي تعمل على منع تخثر الدم) ؛ لأنھ قد یزید من خطر حدوث نزیف غیر طبیع ي &middot;</p><p>استخدام نبتة سانت جونز (ھایبریكوم برفوراتام) (نبتة تُستخدم لعلاج الاكتئاب) - قد یزید التنَّاوُل المتزامن مع عقار سیبرام &middot;</p><p>من خطر الإصابة بآثار جانبیة.</p><p>الأدویة التي تسبب مستویات منخفضة من البوتاسیوم و / أو المغنیسیوم &middot;</p><p>مفلوكین (یُستَخدَم لعلاج الملاریا)، بُوبْرُوبْیُون (یُستَخدَم لعلاج الاكتئاب)، وترامادول (یُستَخدَم لعلاج الألم الشدید) نظرًا &middot;</p><p>للخطورة المُحتَمَلة لانخفاض عتبة إحداث نوبات تشنجیة.</p><p>مضادات الذھان (أدویة علاج الفصام والذھان) نظرًا للخطورة المُحتَمَلة لانخفاض عتبة إحداث نوبات تشنجیة ومضادات &middot;</p><p>الاكتئاب .</p><p>مضادات اضطراب النَّظم من الفئة 1أ و 3، مضادات الذھان (على سبیل المثال: مشتقات الفینتیازین، بیموزید، ھالُوبِیرِیدُول)،&middot;</p><p>مضادات الاكتئاب ثلاثیة الحلقات، بعض الأدویة المضادة للمیكروبات (على سبیل المثال: سبارفلوكساسین،</p><p>موكسیفلوكساسین، إریثرومیسین عن طریق الورید، بنتامیدین، العلاج المضاد للملاریا خاصة ھولوفانترین)، بعض مضادات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الھیستامین (أستیمایزول، میزولاستین).</p><p>تناوُل عقار سيبرام مع الأغذية والمشروبات والكحوليات<br />يُمكِن تناوُل عقار سيبرام مع الطعام أو بدونه (انظر قسم 3: &quot;كيفية تناوُل عقار سيبرام&quot;).</p><p>ثبت أن عقار سيبرام لا يزيد من تأثيرات الكحول. مع ذلك، يُوصى بعدم تناوُل الكحوليات أثناء العلاج بعقار سيبرام.</p><p>الحمل والرَّضاعة الطبيعية والخصوبة<br />إذا كنتِ حاملًا أو تُخَططين للحمل فأبلغي طبيبك. يجب عادةً على السيدات الحوامل تجنُّب تناوُل عقار سيبرام، كما يجب عليهن تجنب إرضاع أطفالهن أثناء تناوُل هذا العلاج ما لم تناقشي مع طبيبك المخاطر والفوائد المترتبة على ذلك.</p><p>إذا تناولتِ عقار سيبرام خلال الأشهر الثلاثة الأخيرة من الحمل وحتى الولادة، فيجب أن تدركي أنه قد تتم ملاحظة الآثار التَّالية في الطفل حديث الولادة: مشاكل بالتَّنفس، جلد مائل إلى الزرقة، نوبات التشنُّج، تغيرات في درجة الحرارة، صعوبات في تناول الطعام، قيء، انخفاض مستوى السكر بالدَّم، تصلُّب العضلات أو مرونتها، ردود أفعال حيَّة، ارتعاش، عصبيّة، هياج، خمول، بكاء متواصل، نعاس، صعوبات في النوم. إذا أُصيب طفلك بأيّ من هذه الأعراض، فيُرجى الاتصال بطبيبك فورًا.</p><p>تأكَّدي من أن ممرضة التوليد الخاصة بكِ و/أو طبيبكِ يعلمون أنكِ تتناولين عقار سيبرام. &nbsp;<br />عند تناوُله أثناء الحمل، لا سيِّما في الأشهر الثلاثة الأخيرة من الحَمْل، قد تُزيد الأدوية المماثلة لعقار سيبرام من خطر حدوث حالة خطيرة في الأطفال الرضع، تُسَمى ارتفاع ضغط الدَّم الرئوي المستمر للمولود الجديد (PPHN)، مما يجعل الطفل يتنفس بصورة أسرع ويبدو لونه يميل إلى اللون الأزرق. عادة ما تبدأ هذه الأعراض أثناء الـ 24 ساعة الأولى بعد ولادة الطفل. إذا حدث هذا لطفلك فيجب عليكِ الاتصال بممرضة التوليد الداية و/ أو الطبيب فورًا.</p><p>إذا كنت تتناول سيبرام بالقرب من نهاية الحمل ، فقد يكون هناك خطر متزايد من حدوث نزيف مهبلي حاد بعد الولادة بفترة وجيزة ، خاصة إذا كان لديك تاريخ من اضطرابات النزيف. يجب أن يكون طبيبك أو ممرضة التوليد على دراية بأنك تتناول سيبرام حتى يتمكنوا من تقديم المشورة لك.</p><p><br />اتَّضح أن سيتالوبرام يقلل من جودة الحيوانات المنوية في الدراسات التي أُجريَت على الحيوانات. من الناحية النظرية، يُمكِن أن يُؤثر هذا على الخصوبة، ولكن لم يلاحظ تأثيره على الخصوبة لدى البشر حتى الآن.</p><p>&nbsp;</p><p>القيادة واستخدام الآلات<br />بوجه عام، لا يُسبب عقار سيبرام النُّعاس، ومع ذلك، إذا شعرت بدوخة أو نعاس عند بدء تناوُل هذا الدَّواء، فتجنَّب القيادة أو استخدام أيّ أدوات أو آلات لحين زوال هذه التأثيرات.</p><p>&nbsp;</p><p>معلومات هامَّة عن بعض مكونات عقار سيبرام<br />إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي الكمية التي يجب أن تتناولها؟</strong></p><p dir="RTL">تناول دائمًا هذا الدَّواء بالضبط كما أخبرك الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا من كيفية التَّناول.</p><p>&nbsp;</p><p dir="RTL"><u>البالغون</u></p><p dir="RTL"><em>الاكتئاب.</em></p><p dir="RTL">الجرعة المعتادة هي 20 مجم يوميًّا. قد يرفع طبيبك الجرعة لتصل بحد أقصى إلى 40 مجم في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اضطراب الهلع</em></p><p dir="RTL">جرعة البداية هي 10 مجم يوميا للأسبوع الأول قبل زيادة الجرعة إلى 20-30 مجم يوميا. يمكن زيادة الجرعة من قبل الطبيب إلى حد أقصى قدره 40 مجم يوميا.</p><p>&nbsp;</p><p dir="RTL"><u>المرضى من كبار السن (الذين تزيد أعمارهم على 65 عامًا)</u></p><p dir="RTL">يجب خفض جرعة البدء إلى نصف الجرعة المُوصى بها، على سبيل المثال: 10-20 مجم في اليوم. يجب ألا يتناول المرضى من كبار السن عادةً جرعة أكبر من 20 مجم يوميًّا.</p><p>&nbsp;</p><p dir="RTL"><u>المرضى المعرضون لمخاطر خاصَّة</u></p><p dir="RTL">يجب ألا يتناول المرضى المصابون بمشاكل بالكبد جرعة أكبر من 20 مجم يوميًّا.</p><p>&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون (الذين تقل أعمارهم عن 18 عامًا)</u></p><p dir="RTL">يجب عدم إعطاء عقار سيبرام للأطفال أو المراهقين. لمزيد من المعلومات، يُرجى الرجوع إلى القسم 2: &quot;ما الذي تحتاج إلى معرفته قبل تناوُل عقار سيبرام؟&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف و متى تناوُل عقار سيبرام</strong></p><p dir="RTL">يتم تناوُل عقار سيبرام يوميًّا كجرعة مفردة.</p><p>&nbsp;</p><p dir="RTL">يمكن تناوُل عقار سيبرام بأيّ وقت من اليوم مع الطعام أو بدونه.</p><p dir="RTL">ابلع الأقراص مع كوب من الماء. لا تمضغ الأقراص (إذ إن طعمها مر).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">مثله مثل أدوية أخرى تستخدم لعلاج الاكتئاب، فقد تستغرق هذه الأقراص بضعة أسابيع قبل أن تجعلك تشعر بأيّ تحسن. استمر في تناوُل عقار سيبرام حتى إذا استغرق الأمر بعض الوقت قبل أن تشعر بأي تحسُّن في حالتك.</p><p>&nbsp;</p><p dir="RTL">لا تغير أبدًا جرعة هذا الدَّواء دون التحدُّث إلى طبيبك أولًا.</p><p>&nbsp;</p><p dir="RTL">تحدد مدة العلاج بشكل فردي، وتستغرق عادةً 6 أشهر على الأقل. استمر في تناوُل هذا الدَّواء طالما أوصاك طبيبك بذلك. لا تتوقف عن تناوُلها حتى إذا بدأت تشعر بتحسن، ما لم يخبرك طبيبك بفعل ذلك. قد يستمر المرض الكامن لمدة طويلة، وإذا توقفت عن تناوُل العلاج مبكرًا، فقد تعود أعراض الاكتئاب.</p><p>&nbsp;</p><p dir="RTL">يستفيد المرضى الذين يعانون من الاكتئاب المتكرر من العلاج المستمر، في بعض الأحيان لعدة سنوات لتجنُّب الإصابة بنوبات اكتئاب جديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية من عقار سيبرام أكثر مما يجب</strong></p><p dir="RTL">إذا كنت تشك بأنك أو بأن شخصًا آخر قد تناول كمية أكثر مما يجب من عقار سيبرام، فاتصل بطبيبك أو بقسم الطوارئ بأقرب مستشفى لك فورًا. قم بهذا حتى إذا لم تظهر لديك أيّ علامات للضيق أو الإصابة بتسمُّم. خذ معك عبوة عقار سيبرام في حال زرت طبيبًا أو مستشفى.</p><p>&nbsp;</p><p dir="RTL">قد تتمثل بعض علامات الجرعة الزائدة في عدم انتظام ضربات القلب المُهَدد للحياة والتشنُّجات والهِياج وتغير النَّظْم القلبي ونُعاس وغيبوبة وقيء وارتعاش وانخفاض ضغط الدَّم وارتفاع ضغط الدَّم وغثيان (شعور بالإعياء) ومتلازمة السيرُوتُونين (انظر قسم: 4) وهياج ودوخة واتساع حدقتي العين وتعرُّق وتلوُّن الجلد باللون الأزرق وزيادة سرعة التنفُّس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا &nbsp;نسيت تناوُل عقار سيبرام</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p>&nbsp;</p><p dir="RTL">إذا &nbsp;نسيت تناوُل جرعة، وتذكرت قبل الذهاب إلى النوم، فتناولها فورًا. استمر في تناوُلها كالمعتاد</p><p dir="RTL">في اليوم التَّالي. إذا تذكرت فقط أثناء الليل أو في اليوم التَّالي، فتجاوز الجرعة التي أغفلتها واستمر كالمعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناوُل عقار سيبرام</strong></p><p dir="RTL">لا تتوقف عن تناوُل عقار سيبرام حتى يخبرك طبيبك بأن تفعل ذلك. عند إتمام دورتك العلاجية، يُنصح بشكل عام بخفض جرعتك من عقار سيبرام تدريجيًّا على مدى عدة أسابيع.</p><p>&nbsp;</p><p dir="RTL">يُؤدي الإيقاف المفاجئ للأدوية إلى أعراض توقف خفيفة ومؤقتة مثل: الدوخة، شعور يشبه وخز الإبر أو المسامير، اضطرابات النوم (أحلام حيَّة، كوابيس، عدم القدرة على النوم)، شعور بالقلق، صداع، شعور بالإعياء (غثيان)، تعرُّق (بما في ذلك التعرُّق الليلي)، شعور بالتململ أو الهياج، ارتعاش، شعور بالارتباك أو التوهان، شعور بالانفعال أو العصبية، إِسْهال (براز لين)، اضطرابات الرؤية، ضربات قلب مضطربة أو قوية (خفقان).</p><p>&nbsp;</p><p dir="RTL">عند إتمام دورتك العلاجية، يُنصح بخفض جرعتك من عقار سيبرام تدريجيًّا على مدى أسبوعين بدلًا من الإيقاف المفاجئ.</p><p dir="RTL">إذا كانت لديكِ أية أسئلة إضافية حول استخدام هذا المنتج، فاستشيري طبيبكِ أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p>مثله مثل جميع الأدوية، قد يُسبب عقار سيبرام آثارًا جانبية، على الرغم من أنها لا تحدث للجميع.</p><p>تزول عادةً الآثار الجانبية بعد بضعة أسابيع من العلاج. يُرجى إدراك أن العديد من الآثار قد تكون أيضًا أعراضًا لمرضك، ومن ثم تتحسن عندما تبدأ في الشعور بتحسن.</p><p>أبلغ بعض المرضى عن الآثار الجانبية الخطيرة التَّالية.</p><p>إذا أصبت بأي من الأعراض التَّالية، فيجب عليك التَّوقف عن تناوُل عقار سيبرام ومراجعة طبيبك فورًا:<br />&bull;&nbsp;&nbsp; &nbsp;حمى مرتفعة، هِياج، ارتباك/التباس، ارتجاف، تقلصات عضلية مفاجئة: قد تكون هذه علامات على الإصابة بحالة نادرة تدعى متلازمة السيروتونين التي تم الإبلاغ عنها مع استخدام مضادات الاكتئاب.<br />&bull;&nbsp;&nbsp; &nbsp;إذا تعرَّضت لتورُّم الجلد أو اللسان أو الشفتين أو الوجه، أو كان لديك صعوبات في التَّنفس أو البلع (تفاعلات حساسية).<br />&bull;&nbsp;&nbsp; &nbsp;نزيف غير مُعتاد، بما في ذلك نزيف الجهاز الهضمي.</p><p>الآثار الجانبية النادرة والخطيرة (قد تؤثر في ما يصل إلى 1 من كل 1000 مريض)<br />إذا أصبت بأي من الأعراض التَّالية، فيجب عليك التَّوقف عن تناوُل عقار سيبرام ومراجعة طبيبك فورًا:<br />&bull;&nbsp;&nbsp; &nbsp;نقص الصوديوم بالدَّم يُمكِن أن يؤدي انخفاض مستويات الصوديوم بالدَّم إلى الشعور بالتَّعب والارتباك والانتفاض العضلي.<br />تكون الآثار الجانبية التَّالية غالبًا طفيفة، وتختفي عادةً بعد بضعة أيام من العلاج. انتبه إلى أنه قد يكون العديد من الآثار الجانبية الواردة أدناه أيضًا أعراضًا لمرضك، ومن ثم تزول عندما تبدأ في الشعور بتحسن.</p><p>إذا سببت لك هذه الآثار الجانبية شعورًا بالضيق أو استمرت لأكثر من بضعة أيام، فأخبر طبيبك.</p><p>يزيد جفاف الفم من خطر الإصابة بنخر الأسنان؛ لذا، يجب عليك تنظيف الأسنان بشكل أكثر تكرارًا من المعتاد.</p><p>شائعة جدًّا (قد تُؤثر على أكثر من 1 من بين كل 10 أشخاص):<br />&bull;&nbsp;&nbsp; &nbsp;النعاس.<br />&bull;&nbsp;&nbsp; &nbsp;صعوبة النوم.<br />&bull;&nbsp;&nbsp; &nbsp;زيادة التعرُّق.<br />&bull;&nbsp;&nbsp; &nbsp;جفاف الفم.<br />&bull;&nbsp;&nbsp; &nbsp;غثيان (شعور بالإعياء).</p><p>شائعة: (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠ أشخاص):<br />&bull;&nbsp;&nbsp; &nbsp;انخفاض الشهية.<br />&bull;&nbsp;&nbsp; &nbsp;هِياج.<br />&bull;&nbsp;&nbsp; &nbsp;ضعف الرغبة الجنسية.<br />&bull;&nbsp;&nbsp; &nbsp;القلق.<br />&bull;&nbsp;&nbsp; &nbsp;العصبية.<br />&bull;&nbsp;&nbsp; &nbsp;حالات من الارتباك.<br />&bull;&nbsp;&nbsp; &nbsp;أحلام غير عادية.<br />&bull;&nbsp;&nbsp; &nbsp;رعشة.<br />&bull;&nbsp;&nbsp; &nbsp;وخز أو تنميل في اليدين أو القدمين.<br />&bull;&nbsp;&nbsp; &nbsp;دوخة.<br />&bull;&nbsp;&nbsp; &nbsp;اضطراب في الانتباه.<br />&bull;&nbsp;&nbsp; &nbsp;طنين بالأذن.<br />&bull;&nbsp;&nbsp; &nbsp;تثاؤب.<br />&bull;&nbsp;&nbsp; &nbsp;إِسْهال.<br />&bull;&nbsp;&nbsp; &nbsp;- القيء.<br />&bull;&nbsp;&nbsp; &nbsp;إمساك.<br />&bull;&nbsp;&nbsp; &nbsp;- حكة.<br />&bull;&nbsp;&nbsp; &nbsp;ألم بالعضلات والمفاصل.<br />&bull;&nbsp;&nbsp; &nbsp;قد يجد الرجال صعوبة في القذف والحصول على الانتصاب.<br />&bull;&nbsp;&nbsp; &nbsp;بالنسبة للإناث، قد يجدن صعوبة في الوصول إلى هِزة الجماع.<br />&bull;&nbsp;&nbsp; &nbsp;إرهاق.<br />&bull;&nbsp;&nbsp; &nbsp;حمّى.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;وخز بالجلد.<br />&bull;&nbsp;&nbsp; &nbsp;انخفاض الوزن.</p><p>غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):<br />&bull;&nbsp;&nbsp; &nbsp;اضطراب النزف الجلدي (سهولة الإصابة بكدمات).<br />&bull;&nbsp;&nbsp; &nbsp;زيادة الشهية.<br />&bull;&nbsp;&nbsp; &nbsp;عدوانية.<br />&bull;&nbsp;&nbsp; &nbsp;تَبَدُّد الشَّخْصِيَّة.<br />&bull;&nbsp;&nbsp; &nbsp;الهلوسة.<br />&bull;&nbsp;&nbsp; &nbsp;الهوس.<br />&bull;&nbsp;&nbsp; &nbsp;الإغماء.<br />&bull;&nbsp;&nbsp; &nbsp;تضخَّم الحدقتين.<br />&bull;&nbsp;&nbsp; &nbsp;سرعة ضربات القلب.<br />&bull;&nbsp;&nbsp; &nbsp;ضربات قلب بطيئة.<br />&bull;&nbsp;&nbsp; &nbsp;طفح القراص.<br />&bull;&nbsp;&nbsp; &nbsp;تساقط الشعر.<br />&bull;&nbsp;&nbsp; &nbsp;طفح جلدي.<br />&bull;&nbsp;&nbsp; &nbsp;حساسية تجاه الضوء.<br />&bull;&nbsp;&nbsp; &nbsp;صعوبة في التبوُّل.<br />&bull;&nbsp;&nbsp; &nbsp;نزيف مفرط أثناء الحيض<br />&bull;&nbsp;&nbsp; &nbsp;تورُّم باليدين أو الساقين.<br />&bull;&nbsp;&nbsp; &nbsp;زيادة الوزن.</p><p>نادرة (في ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):<br />&bull;&nbsp;&nbsp; &nbsp;اختلاجات (تشنجات).&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;حركات لا إرادية.<br />&bull;&nbsp;&nbsp; &nbsp;اضطرابات التَّذوق<br />&bull;&nbsp;&nbsp; &nbsp;نزيف.<br />&bull;&nbsp;&nbsp; &nbsp;التهاب الكبد.</p><p>غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):<br />&bull;&nbsp;&nbsp; &nbsp;أفكار لإيذاء نفسك أو قتلها، انظر أيضًا قسم: &quot;تحذيرات واحتياطات&quot;<br />&bull;&nbsp;&nbsp; &nbsp;انخفاض الصفائح الدَّموية بالدَّم، مما يُزيد من نسبة خطورة حدوث نزيف أو كدمات.<br />&bull;&nbsp;&nbsp; &nbsp;فرط الحساسية (طفح جلدي).<br />&bull;&nbsp;&nbsp; &nbsp;تفاعلات حساسية خطيرة تسبب صعوبة في التَّنفس أو دوخة.<br />&bull;&nbsp;&nbsp; &nbsp;زيادة في كمية البول الذي يتم إخراجه.<br />&bull;&nbsp;&nbsp; &nbsp;نقص بوتاسيوم الدَّم. انخفاض مستويات البوتاسيوم بالدَّم مما قد يُسبب ضعفًا بالعضلات.<br />&bull;&nbsp;&nbsp; &nbsp;الانتفاض العضلي أو اضطراب النَّظْم القلبي.<br />&bull;&nbsp;&nbsp; &nbsp;نوبات هلع.<br />&bull;&nbsp;&nbsp; &nbsp;صريف الأسنان.<br />&bull;&nbsp;&nbsp; &nbsp;التَّمَلْمُل.<br />&bull;&nbsp;&nbsp; &nbsp;حركة عضلات غير عادية أو تصلُّب.<br />&bull;&nbsp;&nbsp; &nbsp;تعذُّر الجلوس (حركات لا إرادية للعضلات).<br />&bull;&nbsp;&nbsp; &nbsp;اضطرابات الرؤية.<br />&bull;&nbsp;&nbsp; &nbsp;انخفاض ضغط الدَّم.<br />&bull;&nbsp;&nbsp; &nbsp;نزيف الأنف.<br />&bull;&nbsp;&nbsp; &nbsp;اضطرابات النزيف وتتضمن نزيف الجلد والأغشية المخاطية (الكدمات).<br />&bull;&nbsp;&nbsp; &nbsp;نزيف مهبلي غزير بعد الولادة بفترة قصيرة (نزيف ما بعد الولادة) ، انظر &quot;الحمل والرضاعة الطبيعية والخصوبة&quot; في القسم 2 لمزيد من المعلومات.</p><p>&bull;&nbsp;&nbsp; &nbsp;تورُّم مفاجئ بالجلد أو الغشاء المخاطي.<br />&bull;&nbsp;&nbsp; &nbsp;ألم أثناء الانتصاب.<br />&bull;&nbsp;&nbsp; &nbsp;تدفُّق اللبن لدى الرجال والسيدات اللاتي لا تمارسن الرضاعة الطبيعية.<br />&bull;&nbsp;&nbsp; &nbsp;عدم انتظام فترة الحيض.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;نتائج غير طبيعية باختبارات وظائف الكبد.<br />&bull;&nbsp;&nbsp; &nbsp;لُوحظ حدوث زيادة خطورة حدوث كسور بالعظام في المرضى ممن يتناولون هذا النوع من الأدوية.<br />&bull;&nbsp;&nbsp; &nbsp;نَظم غير طبيعي للقلب</p><p>إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك. يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.<br />&nbsp;</p><p>&nbsp;</p><p>للإبلاغ عن الأعراض الجانبية:<br />. المملكة العربية السعودية:</p><p dir="ltr">المركز الوطني للتيقظ الدوائي<br />&nbsp; &nbsp; 00966 11 205 &nbsp;7662 :&nbsp; فاكس&nbsp;<br />. &nbsp; &nbsp;مركز الاتصال الموحد : 19999<br />. &nbsp; &nbsp;البريد الالكتروني: npc.drug@sfda.gov.sa<br />. &nbsp; &nbsp;الموقع الالكتروني: https://ade.sfda.gov.sa</p><p><br />.دول مجلس التعاون الخليجي الأخرى:<br />يرجى الاتصال بالسلطات المختصة ذات الصلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية و متناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">يخزن في درجة حرارة أقل من 30 درجة مئوية</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة.</p><p>&nbsp;</p><p dir="RTL">يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p>&nbsp;</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعَّالة هي سيتالوبرام (في هيئة هيدروبروميد).</p><p>&nbsp;</p><p dir="RTL">تحتوي أقراص سيبرام المغلَّفة على 20 مجم سيتالوبرام (في هيئة هيدروبروميد السيتالوبرام).</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي نشا الذرة، اللاكتوز أحادي الهيدرات، سليلوز دقيق التَّبلور، كروسبوفيدون، جليسيرول 85%، كروسكارميلوز الصوديوم، ستيرات الماغنسيوم.</p><p dir="RTL">الغلاف الخارجي: هيبروميلوز 5 وماكروجول 400.</p><p>اللون: ثاني أكسيد التيتانيوم (E 171).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر عقار سيبرام في هيئة أقراص مغلَّفة بتركيز 20 مجم في عبوات شرائط.</p><p>&nbsp;</p><p dir="RTL"><em>وصف أقراص عقار سيبرام </em></p><p dir="RTL">الأقراص بتركيز 20 مجم هي أقراص بيضاوية بيضاء محززة ومغلَّفة تحمل العلامة &quot;C&quot; و&quot;N&quot;.</p><p>&nbsp;</p><p dir="RTL">يتوفر عقار سيبرام في أحجام العبوات التَّالية:</p><p dir="RTL">28 في عبوات شرائط.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتش لوندبيك إيه/ إس</p><p dir="RTL">9 أوتيليافيج</p><p dir="RTL">2500 فالبي</p><p dir="RTL">الدنمارك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Cipram 20 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Cipram 20 mg:	Each tablet contains 20 mg citalopram (as 24.98 mg citalopram hydrobromide)

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

20 mg:	White, oval, scored, film-coated tablets marked “C” and “N” symmetrically around the score.  

The 20 mg tablets can be divided into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Depression and prevention of relapse/recurrence.</p><p>Panic disorder with or without agoraphobia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Posology</u></p><p><em>&nbsp;</em></p><p><em><u>Adults:</u></em></p><p>Citalopram should be administered as a single oral dose of 20&nbsp;mg daily.</p><p>Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily.</p><p><em><u>&nbsp;</u></em></p><p><u>Duration of treatment</u></p><p>The antidepressant effect usually sets in after 2 to 4 weeks. Treatment with antidepressants is symptomatic and must therefore be continued for an appropriate length of time, usually up to 6 months after recovery in order to prevent relapse. In patients with recurrent depression (unipolar) maintenance therapy may need to be continued for a number of years to prevent new episodes.</p><p>&nbsp;</p><p><em>Panic disorder</em></p><p><em><u>Adults:</u></em></p><p>A single oral dose of 10&nbsp;mg is recommended for the first week before increasing the dose to 20&nbsp;mg daily. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily.</p><p>&nbsp;</p><p><em><u>Duration of treatment</u></em></p><p>Maximum effectiveness of citalopram in treating panic disorder is reached after about 3 months and the response is maintained during continued treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Elderly patients (&gt; 65 years of age)</u></em></p><p>For elderly patients the dose should be decreased to half of the recommended dose, e.g. 10-20 mg daily. The recommended maximum dose for the elderly is 20 mg daily.</p><p>&nbsp;</p><p><em><u>Children and adolescents (&lt;18 years)</u></em></p><p>Citalopram should not be used in the treatment of children and adolescents under the age of 18 years, see section 4.4.</p><p>&nbsp;</p><p><em><u>Reduced renal function</u></em></p><p>Dosage adjustment is not required if the patient has mild to moderate renal impairment. Caution is advised in patients with severe renal impairment (creatinine clearance less than 30 mL/min, see section 5.2).</p><p>&nbsp;</p><p><em><u>Reduced hepatic function</u></em></p><p>An initial dose of 10 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily. Caution and extra careful dose titration is advised in patients with severely reduced hepatic function (see section 5.2).</p><p>&nbsp;</p><p><em><u>Poor metabolisers of CYP2C19</u></em></p><p>An initial dose of 10&nbsp;mg daily during the first two weeks of treatment is recommended for patients who are known to be poor metabolisers with respect to CYP2C19. The dose may be increased to a maximum of 20&nbsp;mg daily depending on individual patient response (see section 5.2).</p><p>&nbsp;</p><p><u>Withdrawal symptoms seen on discontinuation of SSRI</u></p><p>Abrupt discontinuation should be avoided. When stopping treatment with citalopram the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see section 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Citalopram tablets are administered as a single daily dose.</p><p>Citalopram tablets can be taken any time of the day without regard to food intake.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

MAOIs (monoamine oxidase inhibitors)

Citalopram should not be given to patients receiving Monoamine Oxidase Inhibitors (MAOIs) (including selegiline in daily doses exceeding 10 mg/day). Citalopram should not be given for fourteen days after discontinuation of an irreversible MAOI or for the time specified after discontinuation of a reversible MAOI (RIMA) as stated in the prescribing text of the RIMA. MAOIs should not be introduced for seven days after discontinuation of citalopram (see section 4.5).

Citalopram is contraindicated in the combination with linezolid unless there are facilities for close observation and monitoring of blood pressure (see section 4.5).

Concomitant treatment with pimozide (see also section 4.5).

Citalopram is contraindicated in patients with known QT interval prolongation or congenital long QT syndrome.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>Treatment of elderly patients and patients with reduced kidney and liver function, see section 4.2.</p><p>Use in children and adolescents under 18 years of age<br />Antidepressants should not be used in the treatment of children and adolescents under age of 18 years. Suicide related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms.</p><p>In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p>Paradoxical anxiety<br />Some patients with panic disorder may experience intensified anxiety symptoms at the start of treatment with antidepressants. This paradoxical reaction usually subsides within the first two weeks of starting treatment. A low starting dose is advised to reduce the likelihood of a paradoxical anxiogenic effect (see section 4.2).</p><p>Hyponatraemia&nbsp;<br />Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported as a rare adverse reaction with the use of SSRIs and generally reverse on discontinuation of therapy. Elderly female patients seem to be at higher risk.</p><p>Suicide/suicidal thoughts or clinical worsening<br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which citalopram are prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.&nbsp;</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.&nbsp;</p><p>A meta analysis of placebo controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>Akathisia/psychomotor restlessness<br />The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.&nbsp;</p><p>Mania<br />In patients with manic-depressive illness a change towards the manic phase may occur. Should the patient enter a manic phase citalopram should be discontinued.</p><p>Seizures<br />Seizures are a potential risk with antidepressant drugs. Citalopram should be discontinued in any patient who develops seizures. Citalopram should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored. Citalopram should be discontinued if there is an increase in seizure frequency.</p><p>Diabetes<br />In patients with diabetes, treatment with an SSRI may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p>Serotonin syndrome<br />In rare cases, serotonin syndrome has been reported in patients using SSRIs. A combination of symptoms such as agitation, tremor, myoclonus, and hyperthermia may indicate the development of this condition. Treatment with citalopram should be discontinued immediately and symptomatic treatment initiated.</p><p>Serotonergic medicines<br />Citalopram should not be used concomitantly with medicinal products with serotonergic effects such as triptans (including sumatriptan and oxitriptan) (including<br />tramadol), and tryptophan.</p><p>Haemorrhage<br />There have been reports of cutaneous bleeding time and/or bleeding abnormalities such as ecchymoses, gynaecological haemorrhages, gastrointestinal bleedings, and other cutaneous or mucous bleedings with SSRIs (see section 4.8). SSRIs/SNRIs may increase the risk of postpartum haemorrhage (see sections 4.6, 4.8). Caution is advised in patients taking SSRIs, particularly with concomitant use of active substances known to affect platelet function or other active substances that can increase the risk of haemorrhage, as well as in patients with a history of bleeding disorders (see section 4.5).</p><p>ECT (electroconvulsive therapy)<br />There is limited clinical experience of concurrent administration of SSRIs and ECT; therefore caution is advisable.</p><p>St. John&acute;s Wort<br />Undesirable effects may be more common during concomitant use of citalopram and herbal preparations containing St John&rsquo;s wort (Hypericum perforatum). Therefore citalopram and St John&rsquo;s wort preparations should not be taken concomitantly (see section 4.5).</p><p>Withdrawal symptoms seen on discontinuation of SSRI treatment<br />Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In a recurrence prevention clinical trial with citalopram, adverse events after discontinuation of active treatment were seen in 40% of patients versus 20% in patients continuing citalopram.</p><p>The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.&nbsp;<br />They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.<br />Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that citalopram should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&rsquo;s needs (see &ldquo;Withdrawal Symptoms Seen on Discontinuation of SSRI, section 4.2).</p><p>Psychosis<br />Treatment of psychotic patients with depressive episodes may increase psychotic symptoms.</p><p>QT interval prolongation<br />Citalopram has been found to cause a dose-dependent prolongation of the QT interval. Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT prolongation or other cardiac diseases (see sections 4.3, 4.5, 4.8, 4.9 and 5.1).</p><p>Caution is advised in patients with significant bradycardia; or in patients with recent acute myocardial infarction or uncompensated heart failure.</p><p>Electrolyte disturbances such as hypokalaemia and hypomagnesaemia increase the risk for malignant arrhythmias and should be corrected before treatment with citalopram is started.</p><p>If patients with stable cardiac disease are treated, an ECG review should be considered before treatment is started.</p><p>If signs of cardiac arrhythmia occur during treatment with citalopram, the treatment should be withdrawn and an ECG should be performed.</p><p>&nbsp;</p><p>Angle-Closure Glaucoma<br />SSRIs including citalopram may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Citalopram should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Excipients</p><p>The tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not receive this medicine.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p><strong>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interactions with other medicinal products and other forms of interaction</strong></p><p><u>&nbsp;</u></p><p><strong>Pharmacodynamic interactions</strong></p><p>&nbsp;</p><p>At the pharmacodynamic level cases of serotonin syndrome with citalopram, moclobemide and buspirone have been reported.</p><p>&nbsp;</p><p><u>Contraindicated combinations</u></p><p><em><u>&nbsp;</u></em></p><p><em>MAO-inhibitors</em></p><p>The simultaneous use of citalopram and MAO-inhibitors can result in severe undesirable effects, including the serotonin syndrome (see section 4.3).</p><p>Cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with a monoamine oxidase inhibitor (MAOI), including the irreversible MAOI selegiline the reversible MAOIs linezolid and moclobemide and in patients who have recently discontinued SSRI and have been started on a MAOI.</p><p>Some cases presented with features resembling serotonin syndrome. Symptoms of an active substance interaction with a MAOI include:</p><p>Hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma (see section 4.3).</p><p>&nbsp;</p><p><em>Pimozide</em></p><p>Co-administration of a single dose of pimozide 2 mg to subjects treated with racemic citalopram 40 mg/day for 11 days caused an increase in AUC and Cmax of pimozide, although not consistently throughout the study. The co-administration of pimozide and citalopram resulted in a mean increase in the QTc interval of approximately 10 msec. Due to the interaction noted at a low dose of pimozide, concomitant administration of citalopram and pimozide is contraindicated.</p><p>&nbsp;</p><p><u>Combinations requiring precaution for use</u></p><p>&nbsp;</p><p><em>Selegiline (selective MAO‑B inhibitor)</em></p><p>A pharmacokinetic / pharmacodynamic interaction study with concomitantly administered citalopram (20 mg daily) and selegiline (10 mg daily) (a selective MAO‑B inhibitor) demonstrated no clinically relevant interactions. The concomitant use of citalopram and selegiline (in doses above 10 mg daily) is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><em>Serotonergic medicinal products</em></p><p><em>Lithium and tryptophan</em></p><p>No pharmacodynamic interactions have been found in clinical studies in which citalopram has been given concomitantly with lithium. However there have been reports of enhanced effects when SSRIs have been given with lithium or tryptophan and therefore the concomitant use of citalopram with these medicinal products should be undertaken with caution. Routine monitoring of lithium levels should be continued as usual.</p><p>&nbsp;</p><p>Co administration with serotonergic medicinal products e.g. opioids (including tramadol) and triptans (including sumatriptan and oxitriptan) may lead to enhancement of 5‑HT associated effects. Until further information is available, the simultaneous use of citalopram and 5-HT agonists, such as sumatriptan and other triptans, is not recommended (see section 4.4).</p><p>&nbsp;</p><p><em>St. John&rsquo;s</em><em> Wort</em></p><p>Dynamic interactions between SSRIs and herbal remedy St John&rsquo;s wort (Hypericum perforatum) can occur, resulting in an increase in undesirable effects (see section 4.4). Pharmacokinetic interactions have not been investigated.</p><p>&nbsp;</p><p><em>Haemorrhage</em></p><p>Caution is warranted for patients who are being treated simultaneously with anticoagulants, medicinal products that affect the platelet function, such as non steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, dipyridamol, and ticlopidine or other medicines (e.g. atypical antipsychotics, phenothiazines, tricyclic antidepressants) that can increase the risk of haemorrhage (see section 4.4).</p><p>Oral anticoagulants enhance haemorrhagic risk; .Patients receiving oral anticoagulants should be carefully monitored when given along with citalopram [AHPO1]&nbsp;</p><p>- Medicinal products inducing hypokalaemia/hypomagnesaemia</p><p>Caution is warranted for concomitant use of hypokalaemia- / hypomagnesaemia-inducing drugs as they, like citalopram, potentially prolong the QT interval.[AHPO2]&nbsp;</p><p>&nbsp;</p><p>- Neuroleptics</p><p>Experience with citalopram has not revealed any clinically relevant interactions with neuroleptics. However, as with other SSRIs, the possibility of a pharmacodynamic interaction cannot be excluded. No pharmacodynamic interactions have been noted in clinical studies in which citalopram has been given concomitantly with benzodiazepines, antihistamines, antihypertensive drugs, beta-blockers and other cardiovascular drugs.[AHPO3]&nbsp;</p><p>&nbsp;[AHPO1]CHYL AHP 27-Mar-2023: Precaution addition is accepted, however, adjusted wording recommended</p><p>&nbsp;[AHPO2]CHYL AHP 27-Mar-2023: Insertion accepted.</p><p>&nbsp;[AHPO3]CHYL AHP 27-Mar-2023:Not accepted, as the statement does not provide any new risk, and as such not justified to be included here.</p><p>&nbsp;</p><p><em>ECT (electroconvusive therapy)</em></p><p>There are no clinical studies establishing the risks or benefits of the combined use of electroconvulsive therapy (ECT) and citalopram (see section 4.4).</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>No pharmacodynamic or pharmacokinetic interactions have been demonstrated between citalopram and alcohol. However, the combination of citalopram and alcohol is not advisable.</p><p>&nbsp;</p><p><em>Medicinal products lowering the seizure threshold</em></p><p>SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold (e.g. antidepressants [tricyclics, SSRIs], neuroleptics [phenothiazines, thioxanthenes, and butyrophenones]), mefloquin, bupropion and tramadol).</p><p>&nbsp;</p><p><em>QT interval prolongation</em></p><p>Pharmacokinetic and pharmacodynamic studies between citalopram and other medicinal products that prolong the QT interval have not been performed. An additive effect of citalopram and these medicinal products cannot be excluded. Therefore, co-administration of citalopram with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics, antipsychotic (e.g. fentiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarian treatment particularly halofantrine), certain antihistamines (astemizole, mizolastine) etc., is contraindicated and &nbsp;should only be prescribed after careful consideration.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pharmacokinetic interactions</strong></p><p><u>&nbsp;</u></p><p>Biotransformation of citalopram to demethylcitalopram is mediated by CYP2C19 (approx. 38%), CYP3A4 (approx. 31%) and CYP2D6 (approx. 31%) isozymes of the cytochrome P450 system. The fact that citalopram is metabolised by more than one CYP means that inhibition of its biotransformation is less likely as inhibition of one enzyme may be compensated by another. Unlike some other SSRIs, citalopram is only a weak inhibitor of this important enzyme system which is involved in the metabolism of many drugs (including antiarrhythmics, neuroleptics, beta-blockers, TCAs and some SSRIs). Protein binding is relatively low (&lt;80%).[AHPO1]&nbsp; Therefore co-administration of citalopram with other medicinal products has very low likelihood of producing pharmacokinetic medicinal product interactions.</p><p>&nbsp;</p><p><em>Food</em></p><p>The absorption and other pharmacokinetic properties of citalopram have not been reported to be affected by food.</p><p>Influence of other medicinal products on the pharmacokinetics of citalopram .</p><p>Co-administration with ketoconazole (potent CYP3A4 inhibitor) did not change the pharmacokinetics of citalopram.</p><p>A pharmacokinetic interaction study of lithium and citalopram did not reveal any pharmacokinetic interactions (see also above).</p><p>&nbsp;</p><p>Cimetidine (potent CYP2D6, 3A4 and 1A2 inhibitor) caused a moderate increase in the average steady state levels of citalopram. Caution advised when administering citalopram in combination with cimetidine. Dose adjustment may be warranted.</p><p>Co-administration of escitalopram (the active enantiomer of citalopram) with omeprazole 30 mg once daily (a CYP2C19 inhibitor) resulted in moderate (approximately 50%) increase in the plasma concentrations of escitalopram. Thus, caution should be exercised when used concomitantly with CYP2C19 inhibitors (e.g. omeprazole, esomeprazole, fluconazole, fluvoxamine, lansoprazole, ticlopidine). A reduction in the dose of citalopram may be necessary based on monitoring of undesirable effects during concomitant treatment.</p><p>&nbsp;</p><p>Metoprolol</p><p>Escitalopram (the active enantiomer of citalopram) is an inhibitor of the enzyme CYP2D6. Caution is recommended when citalopram is co-administered with medicinal products that are mainly metabolised by this enzyme, and that have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6, e.g. antidepressants such as desipramine, clomipramine and nortriptyline or antipsychotics like risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted. Coadministration with metoprolol resulted in a twofold increase in the plasma levels of metoprolol, but did not statistically significant increase the effect of metoprolol on the blood pressure and cardiac rhythm.</p><p>&nbsp;</p><p><u>Effects of citalopram on other medicinal products</u></p><p>&nbsp;</p><p>A pharmacokinetic / pharmacodynamic interaction study with concomitant administration of citalopram and metoprolol (a CYP2D6 substrate) showed a twofold increase in metoprolol concentrations, but no statistically significant increase in the effect of metoprolol on blood pressure and cardiac rhythm in healthy volunteers. Caution is recommended when metoprolol and citalopram are co-administered. Dose adjustment may be warranted.</p><p>&nbsp;</p><p>Citalopram and demethylcitalopram are negligible inhibitors of CYP2C9, CYP2E1 and CYP3A4, and only weak inhibitors of CYP1A2, CYP2C19 and CYP2D6 as compared to other SSRIs established as significant inhibitors.</p><p>&nbsp;</p><p><em>Levomepromazine, digoxin, carbamazepine</em></p><p>No change or only very small changes of clinical importance were observed when citalopram was given with CYP1A2 substrates (clozapine and theophylline), CYP2C9 (warfarin), CYP2C19 (imipramine and mephenytoin), CYP2D6 (sparteine, imipramine, amitriptyline, risperidone) and CYP3A4 (warfarin, carbamazepine (and its metabolite carbamazepine epoxide) and triazolam).</p><p><s>&nbsp;</s></p><p>No pharmacokinetic interaction was observed between citalopram and levomepromazine, or digoxin, (indicating that citalopram neither induce nor inhibit P-glycoprotein).</p><p>&nbsp;</p><p><em>Desipramine, imipramine</em></p><p>In a pharmacokinetic study no effect was demonstrated on either citalopram or imipramine levels, although the level of desipramine, the primary metabolite of imipramine, was increased. When desipramine is combined with citalopram, an increase of the desipramine plasma concentration has been observed. A reduction of the desipramine dose may be needed.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>Pregnancy</p><p>Published data on pregnant women (more than 2500 exposed outcomes) indicate no malformative feto-/ neonatal toxicity. However, citalopram should not be used<br />during pregnancy unless clearly necessary and only after careful consideration of risk/benefit. Neonates should be observed if maternal use of<br />citalopram continues into the later stages of pregnancy, particularly in the third trimester. Abrupt discontinuation should be avoided during pregnancy. The following symptoms may occur in the neonates after maternal SSRI/SNRI use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures,<br />temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either serotonergic effects or discontinuation symptoms. In a majority of instances the<br />complications begin immediately or soon (&lt;24 hours) after delivery. Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase<br />the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5&nbsp;cases per 1000 pregnancies. In the general population 1 to<br />2 cases of PPHN per 1000 pregnancies occur.</p><p>&nbsp;</p><p>Breast-feeding<br />Citalopram is excreted into breast milk. It is estimated that the suckling infant will receive about 5% of the weight related maternal daily dose (in mg/kg). No or only minor<br />events have been observed in the infants. However, the existing information is insufficient for assessment of the risk to the child. The decision whether to continue or discontinue<br />either nursing or citalopram therapy should take into account the risks of citalopram exposure for the infant and the benefits of citalopram treatment for the mother.<br />Caution is recommended.</p><p>&nbsp;</p><p>Fertility<br />Animal data have shown that citalopram may affect sperm quality (see section 5.3). Human case reports with some SSRIs have shown that an<br />effect on sperm quality is reversible. Impact on human fertility has not been observed so far.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Citalopram has minor or moderate influence on the ability to drive and use machines. Psychoactive medicinal products can reduce the ability to make judgements and to react to emergencies. Patients should be informed of these effects and be warned that their ability to drive a car or operate machinery could be affected.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>4.8&nbsp;&nbsp; &nbsp;Undesirable effects<br />&nbsp;&nbsp; &nbsp;<br />Adverse effects observed with citalopram are in general mild and transient. They are most frequent during the first one or two weeks of treatment and usually attenuate subsequently. The adverse reactions are presented at the MedDRA Preferred Term Level.&nbsp;</p><p>For the following reactions a dose-response was discovered: Sweating increased, dry mouth, insomnia, somnolence, diarrhoea, nausea and fatigue.<br />The table shows the percentage of adverse drug reactions associated with SSRIs and/or citalopram seen in either &ge; 1% of patients in double-blind placebo-controlled trials or in the post-marketing period. Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (can not be estimated from the available data).</p><p>&nbsp;</p><p><img alt="" width="1547" height="879" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Number of patients: citalopram / placebo = 1346 / 545</p><p>1 Cases of suicidal ideation and suicidal behaviours have been reported during citalopram therapy or early after treatment discontinuation (see section 4.4).</p><p>2 This event has been reported for the therapeutic class of SSRIs/SNRIs (see sections 4.4 and 4.6).</p><p>3This event has been reported for the therapeutic class of SSRIs/SNRIs (see section 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>Bone fractures<br />Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p>QT interval prolongation<br />Cases of QT prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT interval prolongation of other cardiac diseases (see section 4.3, 4.4, 4.5, 4.9, 5.1).</p><p>Withdrawal symptoms seen on discontinuation of SSRI treatment<br />Discontinuation of citalopram (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when citalopram treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see section 4.2 and 4.4).</p><p>&bull;Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via the national reporting<br />system</p><p>To reports any side effects</p><p>Saudi Arabia:&nbsp;<br />The National Pharmacovigilance Centre (NPC):<br />- Fax: +966-11-205-7662<br />- SFDA Call Center: 19999&nbsp;<br />- E-mail: npc.drug@sfda.gov.sa&nbsp;<br />- Website: https://ade.sfda.gov.sa/</p><p>Other GCC States:&nbsp;</p><p>Please contact the relevant competent authority.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Toxicity</u></p><p>Comprehensive clinical data on citalopram overdose are limited and many cases involve concomitant overdoses of other drugs/alcohol. Fatal cases of citalopram overdose have been reported with citalopram alone; however, the majority of fatal cases have involved overdose with concomitant medications.</p><p><u>&nbsp;</u></p><p><u>Symptoms</u></p><p>The following symptoms have been seen in reported overdose of citalopram: convulsion, tachycardia, somnolence, QT interval prolongation, coma, vomiting, tremor, hypotension, cardiac arrest, nausea, serotonin syndrome, agitation, bradycardia, dizziness, bundle branch block, QRS prolongation, hypertension, and mydriasis, torsade de pointes, stupor, sweating, cyanosis, hyperventilation, and atrial and ventricular arrythmia.</p><p><u>&nbsp;</u></p><p><u>Management</u></p><p>There is no known specific antidote to citalopram. Treatment should be symptomatic and supportive. Activated charcoal, osmotically working laxative (such as sodium sulphate) and stomach evacuation should be considered. If consciousness is impaired the patient should be intubated. ECG and vital signs should be monitored.</p><p>&nbsp;</p><p>ECG monitoring is advisable in case of overdose, in patients with congestive heart failure/bradyarrhythmias, in patients using concomitant medications that prolong the QT interval, or in patients with altered metabolism, e.g. liver impairment.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacotherapeutic group</u><u>:</u> antidepressants, selective serotonin reuptake inhibitors</p><p><u>&nbsp;</u></p><p><u>ATC-code:</u> N 06 AB 04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Biochemical and behavioural studies have shown that citalopram is a potent inhibitor of the serotonin (5‑HT)-uptake. Tolerance to the inhibition of 5‑HT-uptake is not induced by long-term treatment with citalopram.</p><p>&nbsp;</p><p>Citalopram is a very Selective Serotonin Reuptake Inhibitor (SSRI) with no, or minimal, effect on noradrenaline (NA), dopamine (DA) and gamma aminobutyric acid (GABA) uptake.</p><p>Citalopram has no or very low affinity for a series of receptors including 5‑HT<sub>1A</sub>, 5‑HT<sub>2</sub>, DA D<sub>1</sub> and D<sub>2</sub> receptors, &alpha;<sub>1</sub>-, &alpha;<sub>2</sub>-, &beta;-adrenoceptors, histamine H<sub>1</sub>, muscarine cholinergic, benzodiazepine, and opioid receptors.</p><p>&nbsp;</p><p>The main metabolites of citalopram are all SSRIs although their potency and selectivity ratios are lower than those of citalopram. However, the selectivity ratios of the metabolites are higher than those of many of the newer SSRIs. The metabolites do not contribute to the overall antidepressant effect.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Suppression of rapid eye movement (REM) sleep is considered a predictor of antidepressant activity. Like tricyclic antidepressants, other SSRI&rsquo;s and MAO inhibitors, citalopram suppresses REM-sleep and increases deep slow-wave sleep.</p><p>&nbsp;</p><p>Although citalopram does not bind to opioid receptors it potentiates the antinociceptive effect of commonly used opioid analgesics.</p><p>&nbsp;</p><p>In humans citalopram does not impair cognitive (intellectual function) and psychomotor performance and has no or minimal sedative properties, either alone or in combination with alcohol.</p><p>&nbsp;</p><p>Citalopram did not reduce saliva flow in a single dose study in human volunteers and in none of the studies in<br />healthy volunteers did citalopram have significant influence on cardiovascular parameters. Citalopram has no effect on the serum levels of growth hormone. Citalopram like other SSRIs may increase plasma prolactin, an effect secondary to the prolactin stimulating role of serotonin<br />(see section 4.8</p><p>&nbsp;</p><p>In a double-blind, placebo-controlled ECG study in healthy subjects, the change from baseline in QTc (Fridericia-correction) was 7.5 (90%CI 5.9-9.1) ms at the 20 mg/day dose and 16.7 (90%CI 15.0-18.4) ms at the 60 mg day/dose (see sections 4.3, 4.4, 4.5, 4.8 and 4.9).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Absorption </u></p><p>Absorption is almost complete and independent of food intake (T<sub>max</sub> mean 3 hours). Oral bioavailability is about 80%.</p><p>&nbsp;</p><p>Citalopram oral drops, solution have an approximately 25% higher bioavailability compared to tablets.</p><p>&nbsp;</p><p><u>Distribution </u></p><p>The apparent volume of distribution (V<sub>d</sub>)<sub>&acirc;</sub> is about 12-17 L/kg. The plasma protein binding is below 80% for citalopram and its main metabolites.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Citalopram is metabolized to the active demethylcitalopram, didemethylcitalopram, citalopram-N-oxide and an inactive deaminated propionic acid derivative. All the active metabolites are also SSRIs, although weaker than the parent compound. Unchanged citalopram is the predominant compound in plasma. The concentrations of demethylcitalopram and didemethylcitalopram are usually 30-50% and 5-10% of the citalopram concentration, respectively. The biotransformation of citalopram to demethylcitalopram is mediated by CYP2C19 (approx. 38%), CYP3A4 (approx. 31%) and CYP2D6 (approx. 31%).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination half-life (T<sub>&frac12; </sub>) is about 1&frac12; days and the systemic citalopram plasma clearance (Cl<sub>s</sub>) is about 0.3-0.4 L/min, and oral plasma clearance (Cl<sub>oral</sub>) is about 0.4 L/min.</p><p>Citalopram is excreted mainly via the liver (85%) and the remainder (15%) via the kidneys; 12-23% of the daily dose is excreted in urine as unchanged citalopram. Hepatic (residual) clearance is about 0.3 L/min and renal clearance about 0.05-0.08 L/min.</p><p>&nbsp;</p><p><u>Linearity</u></p><p>The kinetics is linear. Steady state plasma levels are achieved in 1-2 weeks. Average concentrations of 300 nmol/L (165-405 nmol/L) are achieved at a daily dose of 40 mg.</p><p>&nbsp;</p><p><u>Elderly patients (&gt; 65 years)</u></p><p>Longer half-lives (1.5-3.75 days) and decreased clearance values (0.08-0.3 L/min) due to a reduced rate of metabolism have been demonstrated in elderly patients. Steady state values were about twice as high in the elderly as in younger patients treated with the same dose.</p><p>&nbsp;</p><p><u>Reduced hepatic function</u></p><p>Citalopram is eliminated more slowly in patients with reduced hepatic function. The half-life of citalopram is about twice as long and steady state citalopram concentrations at a given dose will be about twice as high as in patients with normal liver function.</p><p>&nbsp;</p><p><u>R</u><u>educed renal function</u></p><p>Citalopram is eliminated more slowly in patients with mild to moderate reduction of renal function, without any major impact on the pharmacokinetics of citalopram. At present no information is available for treatment of patients with severely reduced renal function (creatinine clearance &lt; 30 mL/min) (see section 4.2).</p><p>&nbsp;</p><p><u>Polymorphism</u></p><p><em>In vivo </em>investigations have shown that the metabolism of citalopram exhibits no clinically important polymorphism of the sparteine/debrisoquine oxidation (CYP2D6). For CYP2C19, as a precaution, an initial dose of 10 mg should be considered for known poor metabolisers (see section 4.2).&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acute toxicity</u></p><p>Citalopram has low acute toxicity.</p><p>&nbsp;</p><p><u>Chronic toxicity</u></p><p>In chronic toxicity studies there were no findings of concern for the therapeutic use of citalopram.</p><p>&nbsp;</p><p><u>Reproduction studies</u></p><p>Based on data from reproduction toxicity studies (segment I, II and III) there is no reason to have special concern for the use of citalopram in women of childbearing potential.&nbsp;</p><p>Citalopram appears in milk in low concentrations.</p><p>&nbsp;</p><p>Embryotoxicity studies in rats with doses of 56 mg/kg/day, which cause maternal toxicity showed bone anomalies in the region of the vertebral column and ribs. The maternal plasma level was then 2-3 times the therapeutic concentration in man. In rats citalopram did not have any effect on fertility, pregnancy and postnatal development but diminished the birth weight of the pups. Citalopram and its metabolites reach foetal concentrations, which are 10-15 times the maternal plasma level. Clinical experience of use in pregnant women and during lactation is limited.</p><p>&nbsp;</p><p>Animal data have shown that citalopram induces a reduction of fertility index and pregnancy index, reduction in number in implantation and abnormal sperm at exposure well in excess of human exposure.</p><p>&nbsp;</p><p><u>Mutagenic</u><u> and carcinogenic potential</u></p><p>Citalopram has no mutagenic or carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Tablet core:&nbsp;</p><p>Maize starch</p><p>Lactose monohydrate</p><p>Cellulose, microcrystalline</p><p>Copovidone</p><p>Glycerol 85%</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>&nbsp;</p><p>Coating:</p><p>Hypromellose 5</p><p>Macrogol 400</p><p>Titanium dioxide (E&nbsp;171)</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
20 mg: 4 years.

Each pack has an expiry date.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister packs of 14, 28, 56 and 98 tablets.</p><p>100 and 250 tablets in tablet containers of High Density Polyethylene (HDPE) container.</p><p>Unit dose 56 and 98 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
H. Lundbeck A/S
Ottiliavej 9
2500 Valby
Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>